Inhibitory Effect of NO-Releasing Ciprofloxacin (NCX 976) on Mycobacterium tuberculosis Survival

Open Access

1 July 2003

journal article
Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy

Vol. 47 (7) , 2299-2302
https://doi.org/10.1128/aac.47.7.2299-2302.2003

Abstract

Here, we report the antimycobacterial activity of NCX 976, a new molecule obtained adding a NO moiety to the fluoroquinolone ciprofloxacin, on Mycobacterium tuberculosis H37Rv strain, both in a cell-free model and in infected human macrophages. Unlike unaltered ciprofloxacin, NCX976 displayed a marked activity also at low-nanomolar concentrations.

Keywords

This publication has 19 references indexed in Scilit:

Reactive Nitrogen and Oxygen Intermediates and Bacterial Defenses: Unusual Adaptations inMycobacterium tuberculosis
Antioxidants and Redox Signaling, 2002
The Inducible Nitric Oxide Synthase Locus Confers Protection against Aerogenic Challenge of Both Clinical and Laboratory Strains ofMycobacterium tuberculosisin Mice
Infection and Immunity, 2001
What is the Role of Nitric Oxide in Murine and Human Host Defense against Tuberculosis?
American Journal of Respiratory Cell and Molecular Biology, 2001
COMPARISON OF MYCOBACTERIA-INDUCED CYTOTOXICITY AND INFLAMMATORY RESPONSES IN HUMAN AND MOUSE CELL LINES
Inhalation Toxicology, 2001
Nitric oxide and virus infection
Immunology, 2000
Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria
Current Opinion in Microbiology, 2000
A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis
Proceedings of the National Academy of Sciences, 1999
S‐Nitrosylation of Viral Proteins: Molecular Bases for Antiviral Effect of Nitric Oxide
IUBMB Life, 1999
The Clinical Use of Fluoroquinolones for the Treatment of Mycobacterial Diseases
Clinical Infectious Diseases, 1997
Nitric Oxide and Parasitic Disease
Published by Elsevier ,1996